After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced better-than-expected revenue in Q1 CY2026, with ...

BD (Becton, Dickinson and Company) has announced the acquisition of Edwards Lifesciences’ Critical Care product group for $4.2 billion. The acquisition follows Edwards’ previously announced plans to ...

As the market for GLP-1 injections continues to grow, BD aims to ride that wave by providing drugmakers with its prefilled syringes. Biologic medications—including those blockbusters for diabetes and ...

The Elyra TFL system is available in two versions, Elyra and Elyra Plus.

FRANKLIN LAKES, N.J., January 24, 2023 / B3C newswire / --BD (Becton, Dickinson and Company), a leading global medical technology company, is pleased to be a Premium Partner at Pharmapack 2023 – the ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vitor Roque ...

Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organic GAAP and adjusted diluted EPS of $1.07 and $3.35, respectively Company updates full-year fiscal 2025 guidance ...

FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & ...

Becton Dickinson & Co. is set to make additional investments in its U.S. manufacturing network to add capacity for critical medical devices. “BD has a longstanding history as a leading U.S.

Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced in Q1 CY2026, with sales up 5.2% year on year to $4.71 billion. Its non-GAAP profit of $2.90 per share was 4.5% above ...